Clinical outcomes of immune checkpoint inhibitors to treat non-small cell lung cancer patients harboring epidermal growth factor receptor mutations

Table 2 Survival analyses of 85 NSCLC patients with EGFR mutations treated with ICIs

Items	N	ORR	PFS (95%CI)	P	OS (95%CI)	P
Total	85	21.2%	7.2 (5.6–8.9)	–	27.4 (19.2–35.6)	–
ICIs + Chemo	43	27.9%	5.6 (4.8–6.5)		17.6 (11.2–24.1)
ICIs + Anti-VEGFR	23	8.7%	9.9 (5.4–14.4)	0.093	NR	0.000
ICIs + Chemo + Anti-VEGFR	19	21.1%	11.2 (5.0–17.3)		17.4 (6.5–28.2)
Exon 19 deletion	45	20%	5.4 (4.3–6.4)	0.016	17.6 (12.0–23.3)	0.043
L858R mutation	33	24.2%	10.2 (5.2–15.2)		NR
T790M mutation	26	19.2%	5.3 (3.9–6.7)	0.039	16.2 (10.8–21.6)	0.031
Non-T790M mutation	24	16.7%	7.6 (3.6–11.6)		NR
TP53 positive	20	35.0%	12.0 (2.1–21.9)	0.780	NR	0.552
TP53 negative	21	19.0%	7.7 (2.2–13.3)		NR
Prior TKI-PFS < 10 months	49	28.6%	7.4 (5.2–9.7)	0.619	25.6 (14.3–36.9)	0.286
Prior TKI-PFS ≥ 10 months	36	11.1%	6.5 (2.2–10.8)		NR
1^st EGFR-TKI resistance	44	25%	12.0 (8.3–15.7)	0.000	NR	0.001
3^rdEGFR-TKI resistance	37	13.6%	5.2 (4.4–6.0)		16.2 (19.1–35.7)

Abbreviations: EGFR Epidermal growth factor receptor, NSCLC Non-small cell lung cancer, ICIs Immune checkpoint inhibitors, Chemo Chemotherapy, VEGFR Vascular endothelial growth factor receptor, TKI-PFS Tyrosine kinase inhibitors- progression-free survival

ISSN: 1471-2466